Hepatitis Treatment News : U.S. Hepatitis C-Related Health Care Costs to Peak at $9.1B in 2024
A Smart + Strong Site
Subscribe to:
Hep Magazine In Bulk
Hep Newsletter
Join Us:

Back to home » Hepatitis Treatment News » January 2013


January 24, 2013

U.S. Hepatitis C-Related Health Care Costs to Peak at $9.1B in 2024

As the baby boomer population ages and the silent epidemic of hepatitis C—heavily concentrated in this age group—wreaks havoc on millions of livers, the United States will see a peak of both liver disease and associated health care costs during the next two decades, according to a new report published in the journal Hepatology. The study assumed no incremental rise in treatment rates as a consequence of newer direct acting antiviral therapies.  

Among the study’s projections were:

  • The prevalence of cirrhotic patients is expected to peak in 2015 with 626,500 cases.
  • The prevalence of decompensated cirrhosis should peak in 2019 with 107,400 cases.
  • Cases of the liver cancer hepatocellular carcinoma (HCC) will increase to 23,800 cases in 2018 and then decline.
  • Active treatment of hepatitis C virus (HCV) can substantially reduce new infections: If the number of people treated for hep C is doubled to a constant rate of 126,000 per year between 2012 and 2030 and the average sustained viral load (SVR, considered a cure) is increased to 70 percent, by 2030 there will be fewer than 100,000 cases of HCV left in the U.S.  (Down from the current estimated 2.5 million cases.)
  • Mortality from the disease will increase steadily and peak around 2020.
  •  In 2011, the total U.S. health care cost for hep C was $6.5 billion. This burden should peak in 2024 at $9.1 billion, mostly as a result of liver disease: 46 percent of the cost is due to decompensated cirrhosis, 20 percent to compensated cirrhosis and 16 percent to HCC.
To read the study, click here.

Search: hepatitis C, HCV, hep C, baby boomer, health care costs, liver, journal Hepatology, cirrhotic, decompensated cirrhosis, hepatocellular carcinoma, HCC, sustained viral load, SVR, cure, peak.

Scroll down to comment on this story. Click here to visit the Hep Forums and ask questions about this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The Hep team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
Current Issue
Hep TV
Services Directory
Conference News
Top Stories
Treatment News
Hep Exclusives
All About Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis C
HCV/HIV Coinfection
Help Paying For Meds
Clinical Trials
Tell us what you think
Should Medicaid limit access to new hep C drugs?

Hepatitis C Reader Survey
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.